KAMIYA BIOMEDICAL COMPANY（簡(jiǎn)稱KAMIYA）1983年成立于美國(guó)加利福尼亞州，1996年公司遷至華盛頓。KAMIYA公司旨在為生命科學(xué)和醫(yī)療機(jī)構(gòu)提供高品質(zhì)的創(chuàng)新的實(shí)驗(yàn)室研究和診斷工具。 

KAMIYA公司最早研發(fā)的產(chǎn)品是最-前沿的用于信號(hào)轉(zhuǎn)導(dǎo)研究的蛋白激酶抑制劑staurosporine（星形孢菌素）和K252a。1990年，KAMIYA成為美國(guó)第-一家生產(chǎn)細(xì)胞凋亡研究的anti-Fas單克隆抗體的公司。

(KAMIYA公司)

1997年，KAMIYA公司引進(jìn)了一條基于比濁分析法的臨床診斷和免疫分析產(chǎn)品的生產(chǎn)線，開(kāi)發(fā)的產(chǎn)品可用于脂質(zhì)評(píng)價(jià)、凝血、炎癥、糖尿病、營(yíng)養(yǎng)評(píng)估和血清蛋白測(cè)定等。K-ASSAY試劑被認(rèn)定為化學(xué)分析的標(biāo)準(zhǔn)試劑，使用時(shí)無(wú)需混合、溶解、稀釋等繁瑣步驟。

如今，KAMIYA的產(chǎn)品線包括數(shù)千種人和動(dòng)物臨床前試驗(yàn)的生物標(biāo)志物檢測(cè)試試劑盒。此外,KAMIYA公司還為生命科學(xué)領(lǐng)域的研究著提供多種多樣的酶抑制劑、單克隆抗體和多克隆抗體等產(chǎn)品，可用于研究細(xì)胞凋亡、耐藥性、氧化、DNA損傷和修復(fù)、骨骼生物學(xué)、癌癥、心臟病、炎癥、肥胖癥、糖尿病等研究。

(kamiya公司外景圖)

KAMIYA代理商—欣博盛生物科技有限公司
KAMIYA公司在國(guó)內(nèi)有多家代理商，欣博盛生物是其中一家。KAMIYA公司與欣博盛生物公司合作多年，欣博盛生物多年以來(lái)一直在代理KAMIYA品牌，負(fù)責(zé)KAMIYA品牌產(chǎn)品在國(guó)內(nèi)銷售及產(chǎn)品技術(shù)支持。如需詢價(jià)/購(gòu)買KAMIYA的產(chǎn)品，可優(yōu)先聯(lián)系欣博盛生物公司。

KAMIYA部分產(chǎn)品列表：

附：KAMIYA公司英文介紹

KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California and relocated to Seattle, Washington in 1996. Our company's purpose is supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets.

The company's first products were protein kinase inhibitors, staurosporine and its analog, K252a. Staurosporine was discovered in 1977 by Dr. Satoshi Ohmura who is a 2015 Nobel Prize winner. This was the first commercially available staurosporine. Today, staurosporine is one of the most popular research tools in life science research fields.

Today, KAMIYA's life science product lines include thousands of human and animal biomarker assays for preclinical testing with one of the largest selections of ELISA kits in the world. KAMIYA continues to offer a variety of other life science research products including enzyme inhibitors and monoclonal / polyclonal antibodies for use in a variety of fields including apoptosis, multidrug resistance, oxidative / DNA damage and repair, bone biology, cancer, cardiac health, inflammation, stress, obesity, and diabetes.

In 1997, KAMIYA introduced a full line of clinical diagnostic and research immunoassay products for lipid assessment, coagulation, inflammation, diabetes, nutritional assessment, and serum protein measurement based on immunoturbidimetric technology. The K-ASSAY reagents were developed for use on standard chemistry analyzers, requiring no mixing, dissolving, or dilution of reagent or sample, at an exceptional value.

Recently, KAMIYA has introduced new innovative K-ASSAY chemistry analyzer reagents for Insulin, D-Dimer, Factor XIII, Plasma FDP, Serum/Urine FDP, and Total IgE testing.

KAMIYA now has the broadest product line of liquid serum protein immunoassay reagents of any company in the U.S. We supply clinical diagnostic reagents to leading hospitals, medical centers, clinical laboratories, clinical reference labs, research facilities, distributors, and diagnostic instrument companies worldwide.

Look for KAMIYA BIOMEDICAL COMPANY to continue to offer the life science and medical communities with innovative and cutting edge laboratory research and diagnostic tools!